# Ascelia Pharma

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/asceliapharma).

## Overview

Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey. The company focuses on developing and commercializing novel drugs for rare cancer conditions, addressing unmet medical needs. Ascelia Pharma's key products include Orviglance, a contrast agent for liver imaging, and Oncoral, an oral chemotherapy drug. The company is listed on NASDAQ Stockholm under the ticker ACE and aims to become a leader in orphan oncology through strategic partnerships and an expanding product pipeline.

## Products & services

• Orviglance - contrast agent for liver imaging
• Oncoral - oral chemotherapy drug
• Pipeline development for rare cancer drugs
• Commercialization partnerships
• Share saving and incentive programs

- **Contrast Agents** (50%) — Includes Orviglance for liver imaging
- **Chemotherapy Drugs** (30%) — Includes Oncoral, an oral chemotherapy drug
- **Pipeline Development** (20%) — Research and development of new drugs

- Orviglance - contrast agent for liver imaging
- Oncoral - oral chemotherapy drug
- Pipeline development for rare cancer drugs
- Commercialization partnerships
- Share saving and incentive programs

## Customers

Ascelia Pharma primarily targets healthcare providers and hospitals that require specialized drugs for rare cancer conditions. The company's products are designed for patients with specific medical needs, such as those with liver cancer and kidney impairment. The addressable market for Orviglance is estimated at USD 800 million annually, highlighting the significant demand for alternatives to gadolinium-based contrast agents. Ascelia Pharma's strategy involves partnering with established commercialization partners to reach these healthcare providers effectively.

- **Healthcare Providers** (primary) — Purchase specialized cancer drugs for patient treatment
- **Hospitals** (primary) — Use contrast agents for imaging procedures
- **Commercial Partners** (secondary) — Collaborate for drug distribution and commercialization

- Healthcare providers seeking specialized cancer drugs
- Hospitals needing contrast agents for liver imaging
- Patients with liver cancer and kidney impairment
- Medical professionals concerned about gadolinium safety
- Commercial partners for drug distribution

## Geography

Ascelia Pharma is headquartered in Malmö, Sweden, with a significant presence in the US through its base in New Jersey. The company's products are marketed globally, with the US accounting for approximately 45% of the market share for Orviglance. Europe and Japan are also key markets, representing 15% and 10% of the market share, respectively. The company's geographic strategy involves leveraging partnerships to expand its reach in these regions.

- Headquartered in Malmö, Sweden
- US base in New Jersey
- US market accounts for 45% of Orviglance sales
- Europe and Japan are key markets
- Global marketing strategy through partnerships

## Strategy

Ascelia Pharma's strategic priorities include advancing its product pipeline and expanding its market presence through partnerships. The company focuses on launching Orviglance and progressing Oncoral through clinical phases. By partnering with established commercialization entities, Ascelia Pharma aims to minimize investment requirements while maximizing market reach. The company is also committed to strengthening its financial position through strategic financing initiatives.

- **Product Launch** (short-term) — To establish market presence and generate revenue
- **Pipeline Expansion** (medium-term) — To address unmet medical needs and diversify offerings
- **Commercial Partnerships** (short-term) — To leverage established market capabilities

- Advance product pipeline with Orviglance and Oncoral
- Expand market presence through partnerships
- Minimize investment requirements for launches
- Strengthen financial position with strategic financing
- Focus on unmet medical needs in rare cancers

## Risks

Ascelia Pharma faces several risks, including the need for continuous financing to support its development and growth. Market dynamics and financing uncertainties pose challenges to ongoing operations. The company's reliance on partnerships for commercialization introduces dependency risks. Additionally, regulatory hurdles and competition in the pharmaceutical industry are significant risks. The company's financial position is also affected by share-based remuneration and warrant valuations, which can lead to dilution and financial volatility.

- **Financing Needs** [critical] — Continuous funding required for growth and development
- **Regulatory Hurdles** [high] — Compliance with pharmaceutical regulations
- **Partnership Dependency** [medium] — Reliance on partners for commercialization

- Need for continuous financing for development
- Market dynamics and financing uncertainties
- Dependency on commercialization partnerships
- Regulatory hurdles in pharmaceutical industry
- Competition from other drug developers
- Dilution risk from share-based remuneration
- Financial volatility from warrant valuations

## Accounting

Ascelia Pharma's financial statements are influenced by several critical accounting matters. The company uses fair value measurements for warrants, which can lead to financial income or costs without cash impact. Share-based remuneration is recognized over the vesting period, affecting equity and personnel costs. The company also uses alternative performance measures not defined by IFRS, which provide additional insights into financial trends but should be considered alongside IFRS measures. These accounting practices can lead to fluctuations in reported financial results.

- **Fair Value Measurements** — high
- **Share-Based Remuneration** — medium

- Fair value measurements for warrants affect financial income/costs
- Share-based remuneration impacts equity and personnel costs
- Alternative performance measures provide additional insights
- Use of non-IFRS measures alongside IFRS for financial trends

---

*Last updated: 2026-08-11T04:04:50.967778+00:00*